Ameritas Investment Partners’s CytomX Therapeutics CTMX Stock Holding History

Ameritas Investment Partners’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.6K	Buy	+16,154	New	+$61.7K	﹤0.01%	2145
2022 Q2	–	Sell	-5,010	Closed	-$13K	–	3100
2022 Q1	$13K	Hold	5,010	–	–	﹤0.01%	2707
2021 Q4	$22K	Hold	5,010	–	–	﹤0.01%	2596
2021 Q3	$26K	Hold	5,010	–	–	﹤0.01%	2555
2021 Q2	$32K	Hold	5,010	–	–	﹤0.01%	2464
2021 Q1	$39K	Buy	5,010 +1,321	+36%	+$10.5K	﹤0.01%	2229
2020 Q4	$24K	Hold	3,689	–	–	﹤0.01%	2377
2020 Q3	$25K	Hold	3,689	–	–	﹤0.01%	2257
2020 Q2	$31K	Hold	3,689	–	–	﹤0.01%	2106
2020 Q1	$28K	Hold	3,689	–	–	﹤0.01%	1982
2019 Q4	$31K	Hold	3,689	–	–	﹤0.01%	2175
2019 Q3	$27K	Hold	3,689	–	–	﹤0.01%	2224
2019 Q2	$41K	Hold	3,689	–	–	﹤0.01%	2018
2019 Q1	$40K	Buy	3,689 +450	+14%	+$6.65K	﹤0.01%	2011
2018 Q4	$49K	Hold	3,239	–	–	﹤0.01%	1818
2018 Q3	$60K	Hold	3,239	–	–	﹤0.01%	1883
2018 Q2	$74K	Buy	3,239 +689	+27%	+$17.6K	﹤0.01%	1742
2018 Q1	$73K	Hold	2,550	–	–	﹤0.01%	1691
2017 Q4	$54K	Hold	2,550	–	–	﹤0.01%	1884
2017 Q3	$44K	Hold	2,550	–	–	﹤0.01%	1968
2017 Q2	$40K	Buy	2,550 +959	+60%	+$14.5K	﹤0.01%	2049
2017 Q1	$27K	Buy	+1,591	New	+$20.9K	﹤0.01%	2226

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Ameritas Investment Partners's CTMX Position: Q2 2026 in Review

Ameritas Investment Partners opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 16,154 shares worth $60.6K. The stake represents ﹤0.01% of the portfolio and ranks #2145 among its holdings. This is a return to the name: Ameritas Investment Partners previously reported a position in CTMX as recently as Q1 2022.

Ameritas Investment Partners first reported a position in CTMX in Q1 2017 and has held it in 22 quarters since. The position peaked at $74K in Q2 2018. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Ameritas Investment Partners held 16,154 shares of CytomX Therapeutics worth $60.6K as of Q2 2026.
CytomX Therapeutics was a new Ameritas Investment Partners position in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2145 holding.
Ameritas Investment Partners first reported a position in CytomX Therapeutics in Q1 2017 and has held it in 22 quarters since.
Ameritas Investment Partners's CytomX Therapeutics position peaked at $74K in Q2 2018.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.